Randeep Sangha

4.8k total citations · 3 hit papers
72 papers, 2.3k citations indexed

About

Randeep Sangha is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Randeep Sangha has authored 72 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Randeep Sangha's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (16 papers) and Lymphoma Diagnosis and Treatment (12 papers). Randeep Sangha is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (16 papers) and Lymphoma Diagnosis and Treatment (12 papers). Randeep Sangha collaborates with scholars based in Canada, United States and France. Randeep Sangha's co-authors include Charles Butts, John R. Mackey, Jennifer L. Spratlin, Raymond Lai, Darryl Glubrecht, Carol E. Cass, Charles Dumontet, James Young, Laith Dabbagh and Andrew Davies and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Randeep Sangha

70 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

2017 461 citations Robert Marcus, Andrew Davies et al. New England Journal of Medicine profile →
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

2020 223 citations Jonathan E. Rosenberg, Srikala S. Sridhar et al. Journal of Clinical Oncology profile →
Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors

2024 60 citations Sarah Cook, Daniel E. Meyers et al. JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Randeep Sangha Canada	23	1.3k	590	542	490	376	72	2.3k
Ki Y. Chung United States	20	1.6k 1.2×	617 1.0×	702 1.3×	324 0.7×	267 0.7×	62	2.4k
Syma Iqbal United States	29	2.0k 1.5×	901 1.5×	993 1.8×	539 1.1×	679 1.8×	129	3.1k
Morten Mau‐Sørensen Denmark	28	1.2k 0.9×	1.1k 1.9×	527 1.0×	310 0.6×	252 0.7×	130	2.7k
Vinod Ganju Australia	24	2.0k 1.5×	655 1.1×	906 1.7×	316 0.6×	323 0.9×	94	2.7k
Yoichi Naito Japan	27	1.7k 1.3×	623 1.1×	1.1k 2.0×	220 0.4×	284 0.8×	150	2.7k
Lillian Werner United States	29	823 0.6×	711 1.2×	891 1.6×	402 0.8×	558 1.5×	126	2.4k
Wen-Qi Jiang China	27	1.3k 1.0×	268 0.5×	390 0.7×	804 1.6×	363 1.0×	76	2.1k
Thierry Lesimple France	32	2.0k 1.5×	1.2k 2.0×	1.0k 1.9×	476 1.0×	228 0.6×	139	3.3k
Wael A. Harb United States	23	1.4k 1.0×	923 1.6×	759 1.4×	247 0.5×	125 0.3×	118	2.5k
Dahish Ajarim Saudi Arabia	26	1.4k 1.0×	609 1.0×	376 0.7×	552 1.1×	239 0.6×	88	2.4k

Countries citing papers authored by Randeep Sangha

Since Specialization

Citations

This map shows the geographic impact of Randeep Sangha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randeep Sangha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randeep Sangha more than expected).

Fields of papers citing papers by Randeep Sangha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randeep Sangha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randeep Sangha. The network helps show where Randeep Sangha may publish in the future.

Co-authorship network of co-authors of Randeep Sangha

This figure shows the co-authorship network connecting the top 25 collaborators of Randeep Sangha. A scholar is included among the top collaborators of Randeep Sangha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randeep Sangha. Randeep Sangha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Melosky, Barbara, Quincy S. Chu, Rosalyn A. Juergens, et al.. (2025). Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC. Lung Cancer. 208. 108717–108717.

Cook, Sarah, Daniel E. Meyers, Igor Stukalin, et al.. (2024). Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Network Open. 7(1). e2352302–e2352302. 60 indexed citations breakdown →

Navani, Vishal, Daniel E. Meyers, Yibing Ruan, et al.. (2023). Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. Clinical Lung Cancer. 24(3). e152–e159. 2 indexed citations

Thành, Nguyễn Xuân, Truong‐Minh Pham, Alain Tremblay, et al.. (2022). Expected Cost Savings From Low-Dose Computed Tomography Scan Screening for Lung Cancer in Alberta, Canada. JTO Clinical and Research Reports. 3(7). 100350–100350. 5 indexed citations

Rosenberg, Jonathan E., Srikala S. Sridhar, Jingsong Zhang, et al.. (2020). EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma. Journal of Clinical Oncology. 38(10). 1041–1049. 223 indexed citations breakdown →

Conter, Henry Jacob, Scott Owen, Anna Zhou, et al.. (2019). Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC). Journal of Medical Economics. 22(7). 625–637. 25 indexed citations

Evans, William K., Parneet Cheema, Randeep Sangha, et al.. (2019). Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 139. 185–194. 11 indexed citations

Batist, Gerald, Parneet Cheema, Heather L. McArthur, et al.. (2019). A Network Approach to Developing Immuno-Oncology Combinations in Canada. Current Oncology. 26(2). 73–79. 1 indexed citations

Thompson, John A., Robert J. Motzer, Ana M. Molina, et al.. (2018). Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research. 24(18). 4399–4406. 48 indexed citations

10.

Atrafi, Florence, Harry J.M. Groen, Lauren A. Byers, et al.. (2018). A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. Clinical Cancer Research. 25(2). 496–505. 38 indexed citations

11.

Kazemi‐Bajestani, Seyyed Mohammad Reza, Harald Becher, Charles Butts, et al.. (2018). Undiagnosed cardiac deficits in non-small cell carcinoma patients in the candidate population for anti-cachexia clinical trials. Supportive Care in Cancer. 27(4). 1551–1561. 8 indexed citations

12.

Tan, Daniel Shao-Weng, Dae Ho Lee, Ross A. Soo, et al.. (2017). P3.02b-117 Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 12(1). S1264–S1265. 6 indexed citations

13.

Cabanero, Michael, Randeep Sangha, Brandon S. Sheffield, et al.. (2017). Management of Egfr-Mutated Non-Small-Cell Lung Cancer: Practical Implications from a Clinical and Pathology Perspective. Current Oncology. 24(2). 111–119. 21 indexed citations

14.

Marcus, Robert, Andrew Davies, Kiyoshi Ando, et al.. (2017). Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine. 377(14). 1331–1344. 461 indexed citations breakdown →

15.

Chu, Quincy S., Randeep Sangha, Sébastien J. Hotte, et al.. (2014). A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Investigational New Drugs. 32(6). 1226–1235. 7 indexed citations

16.

Chu, Michael P., Sunita Ghosh, Carole Chambers, et al.. (2014). Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(1). 33–39. 80 indexed citations

17.

Sangha, Randeep, Angela M. Davies, Primo N. Lara, et al.. (2011). Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation: Results of a Phase I/II Trial. Journal of Thoracic Oncology. 6(12). 2112–2119. 25 indexed citations

18.

Mack, Philip C., William Holland, Rebekah A. Burich, et al.. (2009). EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(12). 1466–1472. 61 indexed citations

19.

Sangha, Randeep, Primo N. Lara, Philip C. Mack, & David R. Gandara. (2009). Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Current Opinion in Oncology. 21(2). 116–123. 10 indexed citations

20.

Sangha, Randeep & Scott North. (2007). L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer. Expert Opinion on Biological Therapy. 7(11). 1723–1730. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact